TD Cowen analyst Tara Bancroft reiterated a Buy rating on UroGen Pharma (NASDAQ: URGN).The analyst commented, "Q2 Jelmyto sales of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE